Pb1943: The Effects of an Online Curriculum Based Approach to Cme on Hematologist/Oncologists’ Ability to Treat Patients With BTK Inhibitors for B-Cell Malignancies

Abstract

The treatment paradigms for B-cell malignancies including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are rapidly evolving. Fortunately, treatment options for CLL and MCL have expanded considerably in recent years thanks to an improved understanding of the molecular mechanisms underlying this disease. Bruton tyrosine kinase (BTK) inhibitors are one such treatment option. Although BTK inhibitors bring new hope to patients with CLL and MCL, the rapid introduction of these agents has also increased the complexity of treatment, making it challenging for hematologist/oncologists to incorporate these novel therapies into clinical practice. Given how quickly the use of BTK inhibitors in CLL and MCL treatment is evolving, it is difficult for even the most conscientious healthcare providers to stay up to date on advances.